15.10.2012 - Patients in Australia and New Zealand will also receive Almirall's Aclidinium against the lung disease COPD. Invida is the licensing partner.
After the approval of Aclidinium by the European Commission in July and the following deal with Italian Menarini Group to commercialise the drug in most of Europe in July, Barcelona-based Almirall S.A. has inked a marketing partnership with Invida Holdings Private Limited, a member of the Menarini Group, to sell the drug on the fifth continent . Invida gains the commercial rights for Aclidinium in Australia and New Zealand, with the deal including both monotherapy and combination therapy (with Formoterol). Both treatments work against Chronic Obstructive Pulmonary Disease (COPD), where the drug relieves the tension in the muscles around the lungs to improve airflow.
COPD makes breathing difficult and is often caused by cigarette smoking. It is estimated that around 2 million people in Australia suffer from the disease, where it is the sixth most common cause of death among men and seventh among women, Almirall said. Financial details of the agreement have not been disclosed. Eduardo Sanchiz, Chief Executive Officer of Almirall, states: "Together with Invida, we will be able to offer this novel therapy in Australia and New Zealand for COPD. With this new agreement Aclidinium, via partners or Almirall's own salesforce, now has access to over 80% of the COPD world market including the US, Japan, Korea and Europe, where we already have secured four license agreements in total." In Germany and Denmark, Aclidinium bromide is already on the market. It works as a long-acting inhaled muscarinic antagonist - sometimes referred to as an anticholinergic -, which has a long residence time at M3 receptors and a shorter residence time at M2 receptors. It is designed to be rapidly broken down in plasma into two major inactive metabolites, explaining its high topical efficacy but low propensity for systemic anticholinergic effects. When taken by inhalation, Aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more